Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.68 |
| ▸ | HTR2A | P28223 | 2/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.52 |
| ▸ | DPP4 | P27487 | 2/20 | 0.50 |
| ▸ | SCN4A | P35499 | 2/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4672036 | 1.00 | HRH1 (0.68) | HRH1HTR2ATAAR1DPP4SCN4A | |
| SCHEMBL4672537 | 1.00 | HRH1 (0.68) | HRH1HTR2ATAAR1DPP4SCN4A | |
| Hydrochloric Acid SCHEMBL28096115 | 0.97 | HRH1 (0.65) | HRH1HTR2ATAAR1DPP4SCN4A | |
| Hydrochloric Acid SCHEMBL11078856 | 0.97 | HRH1 (0.65) | HRH1HTR2ATAAR1DPP4SCN4A | |
| Bromide SCHEMBL28853590 | 0.97 | HRH1 (0.65) | HRH1HTR2ATAAR1DPP4SCN4A | |
| Iodide SCHEMBL28187751 | 0.97 | HRH1 (0.65) | HRH1HTR2ATAAR1DPP4SCN4A | |
| SCHEMBL2784864 | 0.89 | DPP4 (0.55) | HRH1HTR2ATAAR1DPP4SCN4A | |
| SCHEMBL2781356 | 0.89 | DPP4 (0.55) | HRH1HTR2ATAAR1DPP4SCN4A | |
| SCHEMBL2781359 | 0.89 | DPP4 (0.55) | HRH1HTR2ATAAR1DPP4SCN4A | |
| SCHEMBL3634229 | 0.88 | HRH1 (0.68) | HRH1HTR2ATAAR1DPP4SCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1042293-B9 | SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS AND THEIR PHARMACEUTICAL USE | AMGEN INC (US) | 2008-09-03 | — | — | EP | disclosed |
| EP-1042293-B1 | SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS AND THEIR PHARMACEUTICAL USE | AMGEN INC (US) | 2008-03-19 | — | — | EP | disclosed |
| EP-1448564-B1 | SUBSTITUTED INDOLIZINE-LIKE COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2006-04-19 | — | — | EP | disclosed |
| US-6921762-B2 | Substituted indolizine-like compounds and methods of use | AMGEN INC. (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1448564-A2 | SUBSTITUTED INDOLIZINE-LIKE COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2004-08-25 | — | — | EP | disclosed |
| US-6649604-B2 | Analgesics; antidiabetic agents; antiinflamamtory agents | AMGEN INC. | 2003-11-18 | — | — | US | disclosed |
| US-20030195221-A1 | Substituted indolizine-like compounds and methods of use | AMGEN INC. | 2003-10-16 | — | — | US | disclosed |
| WO-2003044021-A2 | SUBSTITUTED INDOLIZINE-LIKE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2003-05-30 | — | — | WO | disclosed |
| US-20030073704-A1 | Substituted pyridone compounds and methods of use | AMGEN INC. | 2003-04-17 | — | — | US | disclosed |
| US-6420385-B1 | INFLAMMATORY, PAIN AND DIABETES DISEASES, | AMGEN INC. | 2002-07-16 | — | — | US | disclosed |
| US-6174901-B1 | FOR TREATMENT OF RHEUMATOID ARTHRITIS, PAGETS DISEASE, OSTEOPHOROSIS, MULTIPLE MYELOMA, UVEITITIS, ACUTE OR CHRONIC MYELOGENOUS LEUKEMIA, PANCREATIC .BETA. CELL DESTRUCTION, OSTEOARTHRITIS, RHEUMATOID SPONDYLITIS, GOUTY ARTHRITIS ETC. | AMGEN INC. | 2001-01-16 | — | — | US | disclosed |
| US-6096753-A | Substituted pyrimidinone and pyridone compounds and methods of use | AMGEN INC. (US) | 2000-08-01 | — | — | US | disclosed |
| CN-1246857-A | Substituted pyrimidinone and pyridinone compounds and their use | AMGEN INC (US) | 2000-03-08 | — | — | CN | disclosed |
| CN-1244202-A | Tricyclic erythromycin derivatives | ABBOTT LAB (US) | 2000-02-09 | — | — | CN | disclosed |
| EP-0948496-A2 | SUBSTITUTED PYRIMIDINONE AND PYRIDONE COMPOUNDS AND METHODS OF USE | Amgen inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998024780-A2 | SUBSTITUTED PYRIMIDINONE AND PYRIDINONE COMPOUNDS AND THEIR USE | AMGEN INC. (US) | 1998-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195221-A1 | Substituted indolizine-like compounds and methods of use | IL1A, IL1B, IL6 | HRH1 1104/4885HTR2A 442/4885TAAR1 1574/4885 |
| US-20030073704-A1 | Substituted pyridone compounds and methods of use | IL6, IL1B, IL1A | HRH1 681/4885HTR2A 1913/4885TAAR1 1612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.